Literature DB >> 8953097

Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis.

A Armengou, C Porcar, J Mascaró, F García-Bragado.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8953097     DOI： 10.1093/clinids/23.6.1337-a

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  21 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

Review 3.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

4.  Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

Authors:  J Xu; C Onyewu; H J Yoell; R Y Ali; R J Vilgalys; T G Mitchell
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Heteroresistance of Cryptococcus gattii to fluconazole.

Authors:  A Varma; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 6.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

7.  Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

Authors:  P Mondon; R Petter; G Amalfitano; R Luzzati; E Concia; I Polacheck; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

8.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Anna M Schimizzi; Monia Maracci; Daniele Giannini; Flavia Carle; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Authors:  Edward Sionov; Hyeseung Lee; Yun C Chang; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.